MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

Home・Akcijų sąrašas・Microbot Medical Inc

Microbot Medical Inc

Uždarymo kaina

2.1 -0.47

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.08

Max

2.12

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-77K -3.6M
Darbuotojai	20
EBITDA	-79K -3.6M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+310.8% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-23

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	140M
Ankstesnė atidarymo kaina	2.57
Ankstesnė uždarymo kaina	2.1

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

2.52 / 2.57 Palaikymas ir pasipriešinimas

Microbot Medical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-07 23:11; UTC

Uždarbis

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026-01-07 22:55; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026-01-07 21:39; UTC

Pagrindinės rinkos jėgos

Raytheon Down Following Trump Post Criticizing Company

2026-01-07 20:13; UTC

Pagrindinės rinkos jėgos

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026-01-07 20:03; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026-01-07 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-07 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026-01-07 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026-01-07 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026-01-07 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026-01-07 22:48; UTC

Rinkos pokalbiai

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026-01-07 22:46; UTC

Uždarbis

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026-01-07 22:45; UTC

Uždarbis

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026-01-07 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026-01-07 22:42; UTC

Uždarbis

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026-01-07 22:40; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026-01-07 22:31; UTC

Rinkos pokalbiai

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026-01-07 22:22; UTC

Rinkos pokalbiai

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026-01-07 22:01; UTC

Rinkos pokalbiai

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026-01-07 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-07 21:46; UTC

Rinkos pokalbiai

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026-01-07 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026-01-07 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026-01-07 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026-01-07 20:29; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Near Deal for Revolution Medicines -- Update

2026-01-07 20:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026-01-07 19:58; UTC

Rinkos pokalbiai

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026-01-07 19:48; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Akcijų palyginimas

Kainos pokytis

Microbot Medical Inc Prognozė

Kainos tikslas

By TipRanks

310.8% į viršų

12 mėnesių prognozė

Vidutinis 8.75 USD 310.8%

Aukščiausias 12 USD

Žemiausias 5.5 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Microbot Medical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Microbot Medical Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

2.52 / 2.57Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.